[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Daniel Kaplan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100587427","phase-1-the-impact-of-botox-on-neuroimmune-interactions-in-atopic-dermatitis-100587427",false,"NCT06928246","The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis","Pilot Study on Cellular and Molecular Impact of Neuroimmune Interactions in Atopic Dermatitis","AD","Inclusion Criteria:\n\nPhase 1b:\n\n* Patients 18 years or older at time of consent\n* Mild-to-Moderate AD, defined as:\n* BSA ≤ 10%\n* IGA ≤ 3\n* No past biologic therapy\n* No systemic therapy for 3 months\n* No topical therapy for treatment of AD for 4 weeks\n\nPhase 2:\n\n* Patients 18 years or older at time of consent\n* Mild-to-Moderate AD, defined as:\n* BSA ≤ 10%\n* IGA ≤ 3\n* At least one patch of eczema of at least 5 cm in diameter\n* No past biologic therapy\n* No systemic therapy for 3 months\n* No topical therapy for treatment of AD for 4 weeks\n\nExclusion Criteria:\n\nPhase 1b:\n\n* Age less than 18 years old\n* Pregnant or breastfeeding\n* Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure\n* Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks\n* Has used topical therapy for treatment of AD within 4 weeks\n\nPhase 2:\n\n* Patients enrolled in Phase 1\n* Age less than 18 years old\n* Pregnant or breastfeeding\n* Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure\n* Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks\n* Has used topical therapy for treatment of AD within 4 weeks","ALL","18 Years",{"count":20,"type":21},8,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.",[27],"Atopic Dermatitis (AD)",[29,30,31],"Atopic dermatitis","Eczema","Botox","RECRUITING","2026-05-01",{"date":35,"type":36},"2026-05-04","ACTUAL",{"date":38,"type":36},"2025-07-17",{"date":40,"type":21},"2027-01",{"name":42,"class":43},"Daniel Kaplan","OTHER",2,""]